Feb 20 (Reuters) - Acorda Therapeutics Inc:
* ACORDA ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION FOR INBRIJA™ (LEVODOPA INHALATION POWDER)
* ACORDA THERAPEUTICS INC - UNDER PRESCRIPTION DRUG USER FEE ACT (PDUFA), FDA HAS SET A TARGET DATE OF OCTOBER 5, 2018 FOR INBRIJA Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.